Euroopan unioni - suomi - EMA (European Medicines Agency)

clinuvel europe limited - afamelanotide - protoporfyyri, erytropoieetiikka - vahvistimet ja suojaavat aineet - valotoksisuuden ehkäisy aikuispotilailla, joilla on erytropoieettinen protoporfyyri (epp).

Euroopan unioni - suomi - EMA (European Medicines Agency)

acorda therapeutics ireland limited - levodopa - parkinsonin tauti - parkinson-lääkkeet - inbrija on tarkoitettu ajoittainen hoito episodinen moottori vaihtelut (off-jaksot) aikuisilla potilailla, joilla on parkinsonin tauti (pd) hoidetaan levodopa/dopa-dekarboksylaasin estäjä.

Euroopan unioni - suomi - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiset aineet - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastiset aineet - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.